produce vital neurotransmitters in the brain. If MDX succeeds in reaching the market, Alcobra will compete amongst Novartis (NYSE: NVS ), Teva (NYSE: TEVA ), Shire (NASDAQ: SHPG ), Janssen and Lilly (NYSE: LLY ), currently marketing ADHD
NEW YORK, Sept 30 (Reuters) - A federal judge said Novartis AG must face a U.S. government lawsuit accusing the Swiss drugmaker of paying multimillion-dollar kickbacks, including a $9,750 dinner for three at a Japanese restaurant, to induce doctors to prescribe its drugs.
are as follows: Johnson & Johnson (NYSE: JNJ ) Novartis AG (NYSE: NVS ) Pfizer (NYSE: PFE ) Merck & Co. (NYSE: MRK ..... device business and its consumer products segment. Novartis is a Swiss company that generated the Complete Story
69 million Swiss francs as per June 30, 2014 * Says H1 revenue comprising deferred income from license fees paid by Novartis of 0.50 million Swiss francs, unchanged from H1 2013 * Says H1 net loss 23.4 million Swiss francs versus 13.6 million
indication is for the treatment of NRAS-mutant melanoma. The regulatory filing is projected to be made in 2015. Binimetinib was invented by Array BioPharma ( ARRY -1.3% ) and licensed to Novartis ( NVS +0.6% ) in 2010. Post your comment!
conference and published in the New England Journal of Medicine. Given that the data were largely as expected and similar to Novartis ’ competing Mekinist and Tafinlar combination, which was recently acquired from GlaxoSmithKline and targets the same
Sept 27 (Reuters) - Novartis AG : * Afinitor led to unprecedented median overall survival in phase III trial with
Mylan (NASDAQ: MYL ) is already selling a generic version. Another generic version of latanoprost is sold by Novartis (NYSE: NVS ) - it is made by the Alcon subsidiary. Complete Story »
The EMA's CHMP adopts a positive opinion supporting the marketing approval of Novartis ' ( NVS -0.1% ) next-generation somatostatin analog (SSA) Signifor (pasireotide) long-acting release formulation for the treatment
ZURICH, Sept 26 (Reuters) - A committee of the European Medicines Agency (EMA) has recommended Novartis drug Signifor LAR for European Union approval to treat a rare hormonal disorder, the Swiss drugmaker said on Friday.